clinical trial · NCT05268289
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Lupus NephritisIptacopan (part 1)Iptacopan (part 2)Placebo + standard of careIptacopan + placebo
brief summary
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
started
Aug 10, 2022
primary completion
Mar 19, 2026
completion
Sep 28, 2028
last updated
Oct 1, 2026
detailed description
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
official title
An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care With and Without Oral Corticosteroids in Patients With Active Lupus Nephritis Class III-IV, +/- V
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol